Results for the substance seladelpar

Seladelpar is an investigational drug that belongs to the class of peroxisome proliferator-activated receptor (PPAR-delta) agonists. It is being studied for the treatment of liver diseases such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). Seladelpar works by reducing inflammation and improving lipid and glucose metabolism in the liver.

In clinical trials, Seladelpar has shown potential to lower alkaline phosphatase (ALP) levels and other markers of liver inflammation, indicating improved liver function. It is considered a promising option for patients who do not respond adequately to standard treatments, such as ursodeoxycholic acid.

Reported side effects in clinical trials include fatigue, abdominal pain, and, more rarely, elevations in liver enzymes. Since Seladelpar is still in the research phase, its use is limited to clinical trials, and its long-term safety and efficacy are still under evaluation.